Recent developments include securing a $2 million bridge loan from the CEO to support clinical programs, narrowing of losses in the first half of 2025, announcement of Phase 3 bridging trial results for uproleselan, and multiple trading halts and resumptions in late 2024. The company also announced upcoming stock splits in late November 2026.

• In April 2026, Apollomics secured a $2 million unsecured bridge financing from its CEO to support ongoing clinical programs [N2][S2].
• In December 2025, the company reported narrowing of losses in the first half of the year compared to prior periods [N3].
• In December 2024, Apollomics announced results from a Phase 3 bridging trial of uproleselan [N5].
• The company experienced trading halts and resumed trading multiple times in December 2024, meeting Nasdaq compliance on bid price requirements [N6][N7][N8].
• Upcoming stock splits were announced for the week of November 25 to November 29, 2026 [N1].

The company’s lead product candidate, vebreltinib, has shown promising initial clinical results, and the company maintains active clinical development programs. Licensing agreements with upfront payments and potential milestone and royalty revenues provide some financial support. The recent $2 million bridge financing from the CEO indicates internal confidence and provides additional runway for clinical operations. The company’s focus on oncology therapies for difficult-to-treat cancers addresses significant unmet medical needs, which could translate into valuable market opportunities if clinical and regulatory success is achieved.

Apollomics has a history of recurring losses and negative shareholders’ equity, with substantial accumulated deficits. The company’s liquidity position has been constrained, with management expressing substantial doubt about its ability to continue as a going concern without additional financing. The clinical-stage nature of its product candidates means no current commercial revenue, and clinical development carries inherent risks of failure or delay. The company’s reliance on external financing, including related-party bridge loans, and the absence of significant physical assets or diversified revenue streams increase financial risk. Trading halts and volatility in the company’s shares may reflect market uncertainty about its prospects.

Apollomics’ moat is primarily based on its proprietary oncology drug candidates and associated intellectual property rights acquired through a spin-off and subsequent development. The company’s focus on difficult-to-treat and treatment-resistant cancers addresses unmet medical needs, which may provide competitive differentiation if clinical development is successful. Its licensing agreements, such as with LaunXP International, provide potential revenue streams and regional development partnerships. However, as a clinical-stage biotechnology company with no commercial products yet, the moat is contingent on successful clinical and regulatory milestones and the ability to secure ongoing financing to support development.

• Clinical Development Risk: The company’s product candidates are in clinical stages and may fail to demonstrate safety or efficacy, delaying or preventing regulatory approval and commercialization.
• Liquidity and Going Concern Risk: Recurring losses and limited cash reserves create substantial doubt about the company’s ability to continue as a going concern without additional financing.
• Regulatory and Market Risk: The company operates in a highly regulated environment with uncertain market acceptance for its therapies, which may impact future revenue potential.
• Related-Party Financing Risk: The $2 million bridge loan from the CEO is a related-party transaction, which may raise governance and financial risk considerations.

• Apollomics Inc. is a clinical-stage biotechnology company focused on oncology therapies, especially for difficult-to-treat and treatment-resistant cancers [S1].
• Founded in 2015, the company has a pipeline with three product candidates in active clinical development, with vebreltinib as the leading candidate showing promising initial clinical results [S1].
• The company operates through wholly-owned subsidiaries in the US, Australia, Hong Kong, and China, conducting research and development and management services [S1,S2].
• Apollomics is incorporated in the Cayman Islands and is an exempted company with limited liability [S1].
• The company has no significant physical assets and uses leased office facilities, including flexible co-working spaces in China after April 2025 [S1].
• Revenue recognition includes licensing and collaboration agreements, such as a $10 million license agreement with LaunXP International for development and commercialization in Asia excluding mainland China, Hong Kong, and Macau, with $8.5 million recognized as revenue for the year ended December 31, 2025 [S1,S22].
• The company has recurring operating losses and negative shareholders' equity, with an accumulated loss of $711.8 million as of December 31, 2025 [S1].
• For the fiscal year ended December 31, 2024, Apollomics reported zero revenue, a net loss of $53.858 million, and basic and diluted EPS of -$52.8 per share [S1].
• As of December 31, 2024, the company had cash and cash equivalents of approximately $9.77 million, current assets of $10.27 million, current liabilities of $7.40 million, resulting in a current ratio of 1.39 and a cash ratio of 1.32 [S1].
• In March 2026, Apollomics secured a $2 million unsecured bridge loan from its CEO, bearing zero interest, intended to support ongoing clinical operations [S2,N2].
• The company has experienced trading halts and resumed trading multiple times in December 2024, meeting Nasdaq compliance on bid price requirements [N6,N7,N8].
• Apollomics announced results from a Phase 3 bridging trial of uproleselan in December 2024 [N5].
• The company’s financial statements are prepared under IFRS and assume going concern despite material uncertainties due to recurring losses and liquidity constraints [S1].
• Apollomics has no variable interest entities (VIEs) in China and does not intend to establish any [S1].
• The company’s revenue recognition follows IFRS 15, with performance obligations including license grants and initial drug supply [S1,S22].
• The company’s liquidity position as of December 31, 2024, shows sufficient cash balances to meet short-term commitments but management has noted substantial doubt about the ability to continue as a going concern without additional financing [S1].
• The company’s losses have narrowed in the first half of 2025 compared to prior periods [N3].
• Apollomics has announced upcoming stock splits in late November 2026 [N1].